Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: The hepatitis B quality of life instrument, version 1.0

Brennan M R Spiegel, Roger Bolus, Steven Han, Myron Tong, Eric Esrailian, Jennifer Talley, Tram Tran, Jason Smith, Hetal A. Karsan, Francisco Durazo, Bruce Bacon, Paul Martin, Zobair Younossi, Siew Hwa-Ong, Fasiha Kanwal

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Despite the increasing realization that health-related quality of life (HRQOL) is an important outcome in chronic HBV infection, there are no validated, disease-targeted instruments currently available. We sought to develop and validate the first disease-targeted HRQOL instrument in noncirrhotic HBV: the Hepatitis B Quality of Life instrument, version 1.0 (HBQOLv1.0). We established content validity for the HBQOL v1.0 by conducting a systematic literature review, an expert focus group, and cognitive interviews with HBV patients. We administered the resultant questionnaire to 138 HBV patients. We used factor analysis to test hypotheses regarding HRQOL domains and measured construct validity by comparing HBQOL v1.0 scores across several anchors, including viral response to treatment, SF-36 scores, and global health. Finally, we measured test-retest and internal consistency reliability. Content validation revealed that HBV affects multiple aspects of psychological, social, and physical health. The resultant questionnaire summarized this HRQOL impact with 31 items across six subscales: psychological well-being, anticipation anxiety, vitality, disease stigma, vulnerability, and transmissibility. Internal consistency and test-retest reliability were excellent. The HBQOL v1.0 discriminated between viral responders versus nonresponders and correlated highly with SF-36 scores and global health. Conclusion: Patients with chronic HBV infection attribute a wide range of negative psychological, social, and physical symptoms to their condition, even in the absence of cirrhosis or cancer. The HBQOL v1.0 is a valid and reliable measure that captures this HRQOL decrement. This instrument may be useful in everyday clinical practice and in future clinical trials.

Original languageEnglish
Pages (from-to)113-121
Number of pages9
JournalHepatology
Volume46
Issue number1
DOIs
StatePublished - Jul 1 2007
Externally publishedYes

Fingerprint

Chronic Hepatitis B
Hepatitis B
Quality of Life
Psychology
Infection
Focus Groups
Reproducibility of Results
Statistical Factor Analysis
Fibrosis
Anxiety
Clinical Trials
Interviews
Health
Neoplasms

ASJC Scopus subject areas

  • Hepatology

Cite this

Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B : The hepatitis B quality of life instrument, version 1.0. / Spiegel, Brennan M R; Bolus, Roger; Han, Steven; Tong, Myron; Esrailian, Eric; Talley, Jennifer; Tran, Tram; Smith, Jason; Karsan, Hetal A.; Durazo, Francisco; Bacon, Bruce; Martin, Paul; Younossi, Zobair; Hwa-Ong, Siew; Kanwal, Fasiha.

In: Hepatology, Vol. 46, No. 1, 01.07.2007, p. 113-121.

Research output: Contribution to journalArticle

Spiegel, BMR, Bolus, R, Han, S, Tong, M, Esrailian, E, Talley, J, Tran, T, Smith, J, Karsan, HA, Durazo, F, Bacon, B, Martin, P, Younossi, Z, Hwa-Ong, S & Kanwal, F 2007, 'Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: The hepatitis B quality of life instrument, version 1.0', Hepatology, vol. 46, no. 1, pp. 113-121. https://doi.org/10.1002/hep.21692
Spiegel, Brennan M R ; Bolus, Roger ; Han, Steven ; Tong, Myron ; Esrailian, Eric ; Talley, Jennifer ; Tran, Tram ; Smith, Jason ; Karsan, Hetal A. ; Durazo, Francisco ; Bacon, Bruce ; Martin, Paul ; Younossi, Zobair ; Hwa-Ong, Siew ; Kanwal, Fasiha. / Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B : The hepatitis B quality of life instrument, version 1.0. In: Hepatology. 2007 ; Vol. 46, No. 1. pp. 113-121.
@article{77aa4a416c5041258e6b99b6be58241d,
title = "Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: The hepatitis B quality of life instrument, version 1.0",
abstract = "Despite the increasing realization that health-related quality of life (HRQOL) is an important outcome in chronic HBV infection, there are no validated, disease-targeted instruments currently available. We sought to develop and validate the first disease-targeted HRQOL instrument in noncirrhotic HBV: the Hepatitis B Quality of Life instrument, version 1.0 (HBQOLv1.0). We established content validity for the HBQOL v1.0 by conducting a systematic literature review, an expert focus group, and cognitive interviews with HBV patients. We administered the resultant questionnaire to 138 HBV patients. We used factor analysis to test hypotheses regarding HRQOL domains and measured construct validity by comparing HBQOL v1.0 scores across several anchors, including viral response to treatment, SF-36 scores, and global health. Finally, we measured test-retest and internal consistency reliability. Content validation revealed that HBV affects multiple aspects of psychological, social, and physical health. The resultant questionnaire summarized this HRQOL impact with 31 items across six subscales: psychological well-being, anticipation anxiety, vitality, disease stigma, vulnerability, and transmissibility. Internal consistency and test-retest reliability were excellent. The HBQOL v1.0 discriminated between viral responders versus nonresponders and correlated highly with SF-36 scores and global health. Conclusion: Patients with chronic HBV infection attribute a wide range of negative psychological, social, and physical symptoms to their condition, even in the absence of cirrhosis or cancer. The HBQOL v1.0 is a valid and reliable measure that captures this HRQOL decrement. This instrument may be useful in everyday clinical practice and in future clinical trials.",
author = "Spiegel, {Brennan M R} and Roger Bolus and Steven Han and Myron Tong and Eric Esrailian and Jennifer Talley and Tram Tran and Jason Smith and Karsan, {Hetal A.} and Francisco Durazo and Bruce Bacon and Paul Martin and Zobair Younossi and Siew Hwa-Ong and Fasiha Kanwal",
year = "2007",
month = "7",
day = "1",
doi = "10.1002/hep.21692",
language = "English",
volume = "46",
pages = "113--121",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B

T2 - The hepatitis B quality of life instrument, version 1.0

AU - Spiegel, Brennan M R

AU - Bolus, Roger

AU - Han, Steven

AU - Tong, Myron

AU - Esrailian, Eric

AU - Talley, Jennifer

AU - Tran, Tram

AU - Smith, Jason

AU - Karsan, Hetal A.

AU - Durazo, Francisco

AU - Bacon, Bruce

AU - Martin, Paul

AU - Younossi, Zobair

AU - Hwa-Ong, Siew

AU - Kanwal, Fasiha

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Despite the increasing realization that health-related quality of life (HRQOL) is an important outcome in chronic HBV infection, there are no validated, disease-targeted instruments currently available. We sought to develop and validate the first disease-targeted HRQOL instrument in noncirrhotic HBV: the Hepatitis B Quality of Life instrument, version 1.0 (HBQOLv1.0). We established content validity for the HBQOL v1.0 by conducting a systematic literature review, an expert focus group, and cognitive interviews with HBV patients. We administered the resultant questionnaire to 138 HBV patients. We used factor analysis to test hypotheses regarding HRQOL domains and measured construct validity by comparing HBQOL v1.0 scores across several anchors, including viral response to treatment, SF-36 scores, and global health. Finally, we measured test-retest and internal consistency reliability. Content validation revealed that HBV affects multiple aspects of psychological, social, and physical health. The resultant questionnaire summarized this HRQOL impact with 31 items across six subscales: psychological well-being, anticipation anxiety, vitality, disease stigma, vulnerability, and transmissibility. Internal consistency and test-retest reliability were excellent. The HBQOL v1.0 discriminated between viral responders versus nonresponders and correlated highly with SF-36 scores and global health. Conclusion: Patients with chronic HBV infection attribute a wide range of negative psychological, social, and physical symptoms to their condition, even in the absence of cirrhosis or cancer. The HBQOL v1.0 is a valid and reliable measure that captures this HRQOL decrement. This instrument may be useful in everyday clinical practice and in future clinical trials.

AB - Despite the increasing realization that health-related quality of life (HRQOL) is an important outcome in chronic HBV infection, there are no validated, disease-targeted instruments currently available. We sought to develop and validate the first disease-targeted HRQOL instrument in noncirrhotic HBV: the Hepatitis B Quality of Life instrument, version 1.0 (HBQOLv1.0). We established content validity for the HBQOL v1.0 by conducting a systematic literature review, an expert focus group, and cognitive interviews with HBV patients. We administered the resultant questionnaire to 138 HBV patients. We used factor analysis to test hypotheses regarding HRQOL domains and measured construct validity by comparing HBQOL v1.0 scores across several anchors, including viral response to treatment, SF-36 scores, and global health. Finally, we measured test-retest and internal consistency reliability. Content validation revealed that HBV affects multiple aspects of psychological, social, and physical health. The resultant questionnaire summarized this HRQOL impact with 31 items across six subscales: psychological well-being, anticipation anxiety, vitality, disease stigma, vulnerability, and transmissibility. Internal consistency and test-retest reliability were excellent. The HBQOL v1.0 discriminated between viral responders versus nonresponders and correlated highly with SF-36 scores and global health. Conclusion: Patients with chronic HBV infection attribute a wide range of negative psychological, social, and physical symptoms to their condition, even in the absence of cirrhosis or cancer. The HBQOL v1.0 is a valid and reliable measure that captures this HRQOL decrement. This instrument may be useful in everyday clinical practice and in future clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=34547457680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547457680&partnerID=8YFLogxK

U2 - 10.1002/hep.21692

DO - 10.1002/hep.21692

M3 - Article

C2 - 17596882

AN - SCOPUS:34547457680

VL - 46

SP - 113

EP - 121

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -